MedTrace Logo

Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis

NCT07536841 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 82

Last updated 2026-05-19

No results posted yet for this study

Summary

This ambispective observational study aims to validate the Odesa Criteria 2026 (OC26), a flexible domain-based point scoring system for diagnosing autoimmune pancreatitis. The study evaluates diagnostic accuracy and reproducibility of OC26 across clinical, serological, morphological, and histological domains.

Conditions

  • Autoimmune Pancreatitis
  • IgG4-Related Diseases
  • Pancreatic Cancer
  • Chronic Pancreatitis

Interventions

OTHER

No intervention (observational study)

Participants receive no assigned intervention. Diagnostic evaluation follows routine clinical practice.

Sponsors & Collaborators

  • Military Medical Clinical Center of the Southern Region, Ukraine

    lead OTHER

Principal Investigators

  • Oleg Dovbenko · Odesa Regional Clinical Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2026-10-01
Completion
2026-12-31

Countries

  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07536841 on ClinicalTrials.gov